190 related articles for article (PubMed ID: 28409191)
1. The Summit for Cancer Immunotherapy (Summit4CI), June 26-29, 2016 Halifax, Canada.
Wouters MCA; Laumont CM; Chen B; Han SJ; Matuszewska K; Potts K; Boudreau JE; Krawczyk CM
Cancer Immunol Immunother; 2017 Jun; 66(6):811-818. PubMed ID: 28409191
[No Abstract] [Full Text] [Related]
2. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
[TBL] [Abstract][Full Text] [Related]
5. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
6. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
Zhang B; Cheng P
Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
[TBL] [Abstract][Full Text] [Related]
7. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
8. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of efficacy in cancer immunotherapy: 14th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 10-12, 2016.
Theelen J; Braun J; Hörzer H; Kloke BP; Ott M; Pizzitola I; Schirmer U; Miller M
Cancer Immunol Immunother; 2017 May; 66(5):673-681. PubMed ID: 28251274
[No Abstract] [Full Text] [Related]
10. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
11. 8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015--May 20-22, Vancouver, Canada.
Boudreau JE; Wouters MC; Krawczyk CM
Cancer Immunol Immunother; 2016 Feb; 65(2):235-41. PubMed ID: 26759005
[No Abstract] [Full Text] [Related]
12. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.
Locy H; de Mey S; de Mey W; De Ridder M; Thielemans K; Maenhout SK
Front Immunol; 2018; 9():2909. PubMed ID: 30619273
[TBL] [Abstract][Full Text] [Related]
15. Role of NK cells in immunotherapy and virotherapy of solid tumors.
Cantoni C; Grauwet K; Pietra G; Parodi M; Mingari MC; De Maria A; Favoreel H; Vitale M
Immunotherapy; 2015; 7(8):861-82. PubMed ID: 26314197
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus immunotherapy: future prospects for oncology.
Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
[TBL] [Abstract][Full Text] [Related]
17. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
Crupi MJF; Bell JC; Singaravelu R
Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viruses: focusing on the tumor microenvironment.
de Vries CR; Kaufman HL; Lattime EC
Cancer Gene Ther; 2015 Mar; 22(4):169-71. PubMed ID: 25721204
[No Abstract] [Full Text] [Related]
19. Oncolytic viruses-immunotherapeutics on the rise.
Keller BA; Bell JC
J Mol Med (Berl); 2016 Sep; 94(9):979-91. PubMed ID: 27492706
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses and immunity.
Chaurasiya S; Chen NG; Fong Y
Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
